INCB 50465-204 (CITADEL-204) (R/R)

INCB 50465-204 (CITADEL-204) (R/R)

A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (MZL) With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)


Study Treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link